pooled-shrna-library-screening-to-identify-factors-that-modulate-drug

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Understanding clinically relevant driver mechanisms of acquired chemo-resistance is crucial for elucidating ways to circumvent resistance and improve ...

Christian Medical College

Thiruvalluvar University

Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab-ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.

Saswati Das

Department of Clinical Haematology

Christian Medical College

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Saswati Das

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Clinical Haematology

Christian Medical College

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Department of Clinical Haematology